Neoadjuvant therapy is widely recognised as an effective treatment option for locally advanced breast cancer of any subtype, as well as early-stage HER2-positive (HER2+) and triple-negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and breast carcinoma.